Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith C Bible

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Antioxidants & Redox Signaling|November 13, 2008
The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductaseJennifer D Tibodeau, Linda M Benson, Crescent R Isham, et al.
Blood|November 9, 2006
Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stressCrescent R Isham, Jennifer D Tibodeau, Wendy Jin, et al.
The Journal of Clinical Endocrinology and Metabolism|September 30, 2015
Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology GroupKeith C Bible, Gilbert J Cote, Michael J Demeure, et al.
Cancer Treatment Reviews|April 29, 2018
Management of treatment-related toxicities in advanced medullary thyroid cancerMarcia S Brose, Keith C Bible, Laura Q M Chow, et al.
Advances in Radiation Oncology|March 21, 2018
External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytomaWilliam Breen, Irina Bancos, William F Young, et al.
The Journal of Clinical Endocrinology and Metabolism|March 18, 2014
Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitorsCrescent R Isham, Brian C Netzel, Ayoko R Bossou, et al.
Head & Neck|October 28, 2024
Pemetrexed-carboplatin salvage therapy in advanced thyroid cancersKenzie K Lee, John C Morris, Aditi Kumar, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 18, 2017
OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERSSina Jasim, Nicole M Iniguez-Ariza, Crystal R Hilger, et al.
Endocrine|July 8, 2017
Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paragangliomaSina Jasim, Vera J Suman, Camilo Jimenez, et al.
Journal of the Endocrine Society|July 16, 2020
Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical CarcinomaKevin C Miller, Ashish V Chintakuntlawar, Crystal Hilger, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Antioxidants & Redox Signaling|November 13, 2008
The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductaseJennifer D Tibodeau, Linda M Benson, Crescent R Isham, et al.
Blood|November 9, 2006
Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stressCrescent R Isham, Jennifer D Tibodeau, Wendy Jin, et al.
The Journal of Clinical Endocrinology and Metabolism|September 30, 2015
Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology GroupKeith C Bible, Gilbert J Cote, Michael J Demeure, et al.
Cancer Treatment Reviews|April 29, 2018
Management of treatment-related toxicities in advanced medullary thyroid cancerMarcia S Brose, Keith C Bible, Laura Q M Chow, et al.
Advances in Radiation Oncology|March 21, 2018
External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytomaWilliam Breen, Irina Bancos, William F Young, et al.
The Journal of Clinical Endocrinology and Metabolism|March 18, 2014
Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitorsCrescent R Isham, Brian C Netzel, Ayoko R Bossou, et al.
Head & Neck|October 28, 2024
Pemetrexed-carboplatin salvage therapy in advanced thyroid cancersKenzie K Lee, John C Morris, Aditi Kumar, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 18, 2017
OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERSSina Jasim, Nicole M Iniguez-Ariza, Crystal R Hilger, et al.
Endocrine|July 8, 2017
Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paragangliomaSina Jasim, Vera J Suman, Camilo Jimenez, et al.
Journal of the Endocrine Society|July 16, 2020
Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical CarcinomaKevin C Miller, Ashish V Chintakuntlawar, Crystal Hilger, et al.
Pageof 6